Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use
Coeptis Therapeutics Holdings (Nasdaq: COEP) has expanded its license agreement with Deverra Therapeutics to include pandemic preparedness and emergency use applications for their allogeneic natural killer (NK) cell technology. The expanded license now covers the use of unmodified NK cells for treating viral infections, pandemic-related illnesses, and emergency stockpiling. This builds upon their August 2023 agreement, which included an allogeneic stem cell expansion platform, two IND applications, and two Phase 1 clinical trials investigating DVX201 as an unmodified NK cell therapy.
Coeptis Therapeutics Holdings (Nasdaq: COEP) ha ampliato il proprio accordo di licenza con Deverra Therapeutics per includere applicazioni di preparazione pandemica e uso emergenziale per la loro tecnologia di cellule natural killer (NK) allogeniche. L'accordo di licenza ampliato copre ora l'uso di cellule NK non modificate per il trattamento di infezioni virali, malattie correlate a pandemie e stoccaggio di emergenza. Questo si basa sull'accordo di agosto 2023, che includeva una piattaforma di espansione di cellule staminali allogeniche, due domande IND e due studi clinici di Fase 1 che indagano DVX201 come terapia con cellule NK non modificate.
Coeptis Therapeutics Holdings (Nasdaq: COEP) ha ampliado su acuerdo de licencia con Deverra Therapeutics para incluir aplicaciones de preparación para pandemias y uso de emergencia para su tecnología de células asesinas naturales (NK) alogénicas. La licencia ampliada ahora abarca el uso de células NK no modificadas para tratar infecciones virales, enfermedades relacionadas con pandemias y almacenamiento de emergencia. Esto se basa en su acuerdo de agosto de 2023, que incluía una plataforma de expansión de células madre alogénicas, dos solicitudes IND y dos ensayos clínicos de Fase 1 que investigan DVX201 como terapia con células NK no modificadas.
Coeptis Therapeutics Holdings (Nasdaq: COEP)는 Deverra Therapeutics와의 라이선스 계약을 확대하여 그들의 동종 자연 살해 세포(NK) 기술에 대한 팬데믹 대비 및 응급 사용 애플리케이션을 포함하였습니다. 확대된 라이선스는 이제 바이러스 감염, 팬데믹 관련 질병 및 응급 비축을 치료하기 위한 비수정 NK 세포의 사용을 포함합니다. 이는 2023년 8월의 계약을 기반으로 하며, 그 계약에는 동종 줄기세포 확장 플랫폼, 두 개의 IND 신청 및 수정되지 않은 NK 세포 요법으로서 DVX201을 조사하는 두 개의 1상 임상 시험이 포함되어 있었습니다.
Coeptis Therapeutics Holdings (Nasdaq: COEP) a élargi son accord de licence avec Deverra Therapeutics pour inclure des applications de préparation aux pandémies et d'utilisation d'urgence pour leur technologie de cellules tueuses naturelles (NK) allogéniques. La licence élargie couvre désormais l'utilisation de cellules NK non modifiées pour traiter les infections virales, les maladies liées aux pandémies et le stockage d'urgence. Cela s'appuie sur leur accord d'août 2023, qui comprenait une plateforme d'expansion de cellules souches allogéniques, deux demandes IND et deux essais cliniques de phase 1 investiguant DVX201 en tant que thérapie par cellules NK non modifiées.
Coeptis Therapeutics Holdings (Nasdaq: COEP) hat seine Lizenzvereinbarung mit Deverra Therapeutics erweitert, um Anwendungen zur Pandemiebereitschaft und für den Notfalleinsatz ihrer allogenen natürlichen Killer(NK)-Zelltechnologie einzubeziehen. Die erweiterte Lizenz umfasst nun die Verwendung von unmodifizierten NK-Zellen zur Behandlung von Virusinfektionen, pandemiebezogenen Erkrankungen und für Notfalllagerung. Dies baut auf ihrer Vereinbarung aus dem August 2023 auf, die eine Plattform zur Expansion allogener Stammzellen, zwei IND-Anträge und zwei klinische Studien der Phase 1 zur Untersuchung von DVX201 als unmodifizierte NK-Zelltherapie umfasst.
- Expanded license agreement broadens potential market applications
- Addition of pandemic and emergency use capabilities creates new revenue opportunities
- Strategic alignment with existing pipeline for cancer, autoimmune and infectious diseases
- None.
Insights
The expanded license agreement significantly enhances COEP's market potential in the rapidly growing NK cell therapy space. The inclusion of pandemic preparedness and emergency use applications opens up substantial government contracting opportunities, particularly through agencies like BARDA and the Strategic National Stockpile. The company's DVX201 platform, with two Phase 1 trials already underway, provides a strong foundation for these expanded applications.
The ability to stockpile NK cells for emergency response represents a strategic advantage, as there's increasing government focus on biodefense and pandemic preparedness following COVID-19. The potential application in Acute Radiation Sickness (ARS) is particularly noteworthy, as few approved treatments exist for this condition. However, the path to commercialization will require significant capital investment and successful clinical validation.
In August 2023, Coeptis secured its exclusive license to key assets from Deverra, including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) applications, and two Phase 1 clinical trial stage assets investigating DVX201 as an unmodified NK cell therapy generated from pooled donor CD34+ cells. These assets expand Coeptis' pipeline and align with the Company's mission to develop treatments for targeting cancer, autoimmune and infectious diseases.
The revised license agreement now enables Coeptis to expand its field of use in the event of:
- Pandemic-Related and Emergency Preparedness: Utilizing unmodified NK cells as treatment of illnesses and injury arising from a pandemic, or act of terror or war, including but not limited to Acute Radiation Sickness (ARS)
- Stockpiling and Emergency Use Situations: Allowing unmodified NK cells to be produced and stored in advance, to stay prepared in advance of future health crisis.
"We are delighted to expand our field of use to now include pandemic and emergency situations, as it now broadens the applicability of NK cells to ensure that we are prepared for future health crises and potentially address long term side effects that may arise as a result of a pandemic," said Dave Mehalick, President and CEO of Coeptis Therapeutics.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-expands-license-agreement-with-deverra-to-include-pandemic-preparedness-and-emergency-use-302285373.html
SOURCE Coeptis Therapeutics, Inc.
FAQ
What is the expanded license agreement between Coeptis Therapeutics (COEP) and Deverra Therapeutics?
What new applications are included in Coeptis Therapeutics' (COEP) expanded license agreement?
When did Coeptis Therapeutics (COEP) initially secure its license with Deverra?
